Table 2 Group one sub groups in COVID-19 pandemic: Demographic, clinical, and laboratory findings (COVID-19 positive vs COVID-19 negative)
From: Effect of COVID-19 on Kawasaki Disease: Decrease Age of Onset and Increase Skin Manifestation
Characteristics | Total (n = 32) | COVID-19 Positive cases (n = 22) | COVID-19 Negative cases (n = 10) | P-value |
|---|---|---|---|---|
Age | 4.38 | 4.32 | 4.50 | 0.967 |
Male% | 65% (n = 21) | 72% (n = 16) | 50% (n = 5) | 0.725 |
Hospital course (days) | 5.13 | 5.77 | 3.70 | 0.212 |
Conjunctivitis | 14 (44%) | 10 (45.5%) | 4 (40%) | 0.773 |
Lymphadenopathy | 9 (28%) | 7 (31.8%) | 2 (20%) | 0.491 |
Oral mucosa or lips changes | 16 (50%) | 11 (50%) | 5 (50%) | 0.315 |
Rash | 19 (59%) | 16 (72%) | 3 (30%) | 0.023 |
Extremity changes | 19 (59%) | 13 (59%) | 6 (60%) | 0.961 |
Abnormal echocardiography findings (regarding coronary arteries) | 11 (34%) | 7 (31.8%) | 4 (40%) | 0.04 |
ESR(mm/h) | 75.79 | 71.05 | 86.23 | 0.398 |
CRP (mg/L) | 50.39 | 53.86 | 43.10 | 0.269 |
Elevated D-Dimer | - | 5 (22.7%) | - | - |
Elevated Ferritin | - | 3 (13.6%) | - | - |
Elevated LDH | - | 3 (13.6%) | - | - |
Elevated Fibrinogen | - | 2 (9.09%) | - | - |
Elevated Procalcitonin | - | 2 (9.09%) | - | - |
Decreased ALBumin | - | 6 (27.2%) | - | - |